Background: Diabetes mellitus prevalence is increasing among women of child-bearing age. Diabetic pregnancy is associated with major maternal and fetal risks, and these can be reduced by preconception care. Pregnancy can be planned using appropriate effective contraception. The objective of this study was to assess diabetic patients' knowledge about pregnancy and to describe their contraceptive use.
Study Design: An observational study was conducted from February to July 2020 at Reims University Hospital, France. Inclusion criteria were: women aged 18 to 40years, with type 1 (T1D) or type 2 diabetes (T2D). Patients filled out a survey about contraceptive use and knowledge regarding diabetic pregnancy and data were completed from medical records.
Results: Eighty-nine T1D and 33 T2D patients were included, with mean ages of 27.9±6.3 and 32.6±4.6years, respectively. Seventy-five percent reported that they had been informed about pregnancy-related risks and 67% about the need to plan pregnancy. The preconception HbA1c target was known by 33% of patients. Appropriate knowledge about pregnancy was greater in T1D patients (65.9%, versus 36.4% in T2D patients; P=0.003). The rate of patients using an effective contraceptive method was 66.4%. Fifteen percent patients for whom contraception was recommended reported having no contraceptive method; 12.5% of contraception users were using a contraindicated method.
Conclusion: A large majority of diabetic women were aware of pregnancy-related risks and the importance of pregnancy planning, but there are still gaps, especially in T2D patients. We need to improve our practices by providing more information and better access to appropriate effective contraception.
Gov Number: NCT04350879.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ando.2022.01.007 | DOI Listing |
Alzheimers Dement
December 2024
University of Virginia, Charlottesville, VA, USA.
Background: The microvasculature of the central nervous system (CNS), which delivers oxygen and nutrients and forms a critical barrier protecting the CNS, is deleteriously affected by both Alzheimer's Disease (AD) and Type 2 Diabetes (T2D). Previous studies have shown pericyte dropout and vessel constriction in brain capillaries in AD, while other studies have shown pericyte bridging and dropout in retinal capillaries in T2D. T2D patients have increased risk of AD, suggesting potentially related microvascular pathological mechanisms.
View Article and Find Full Text PDFJ Endocrinol
January 2025
S Zoungas, School of Public Health and Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Australia.
Tirzepatide is a first-in-class dual agonist at receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) for the treatment of T2D and obesity with unprecedented efficacy for glycaemic control and reductions in body weight as well as improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists. To date, clinical trials of tirzepatide have fulfilled the requirement by regulatory authorities of demonstrated cardiovascular safety in high-risk patients. Whether cardiovascular benefits will be found with dual GLP-1/GIP receptor agonists remains uncertain, and the contribution of GIP receptor activation to cardiovascular risk has not been established.
View Article and Find Full Text PDFCardiovasc Diabetol
January 2025
Department of Nuclear Cardiology, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.
Background: Adipose tissue distribution plays a crucial role in the development of cardiovascular complications. In particular, visceral adipose tissue (VAT) has been linked to insulin resistance (IR) and cardiovascular disease (CVD). However, the relationship between VAT, cardiac dysfunction and the meditation capacity of VAT related to IR has not been fully characterized.
View Article and Find Full Text PDFSci Rep
January 2025
Siriraj Health Policy Unit, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chronic kidney disease (CKD) in type 2 diabetes (T2D) patients is associated with end-stage renal disease and significant economic burden. While sodium glucose cotransporter-2 inhibitors (SGLT2i) show renal benefits in randomized controlled trials (RCTs), their cost-effectiveness in Thailand remains unclear. This study evaluates the cost-utility of adding SGLT2i (dapagliflozin, empagliflozin, and canagliflozin) to standard of care therapy (SoCT) for T2D patients with CKD in Thailand.
View Article and Find Full Text PDFDiabetes Res Clin Pract
December 2024
Diabetes Research Centre, College of Life Sciences, Department of Population Health Sciences, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, Leicester, UK; Leicester British Heart Foundation Centre of Research Excellence, Leicester, UK.
Aims: The aim of this study was to systematically review recommendations on physical activity for adults with type 2 diabetes (T2D).
Methods: Online databases were searched for clinical practice guidelines (CPG), statements, and recommendations. Two authors screened the guidelines based on eligibility criteria.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!